Pharma Profits Continue Leading the Rally: Top Performers

644212072 = GaudiLab|||

Markets slumped yesterday as the Trump administration rattled markets with “weaker dollar” rhetoric. But momentum seems to be recovering today, with indexes broadly posting solid gains at the time of this writing. With the EU’s Mario Draghi endorsing a stronger Euro, international currency politics may remain a market focus in the coming months.

The pharmaceutical sector continues to dominate our Top Performer reports as investors search for hidden growth potential. Today, our Top Gainers were lead by a cluster of pharma stocks, two of which we highlight below.

Summit Therapeutics (SMMT): jumps on promising clinical trial results.

SMMT focuses on developing therapies for rare diseases and infectious diseases. This morning, they announced positive clinical trial results from “PhaseOut DMD.” Indicators suggest it holds substantial potential as a treatment for Duchenne muscular dystrophy.

Investors bought the stock heavily after getting wind of the announcement, driving the stock up over 20% at the time of this writing.

Iovance Biotherapeutics (IOVA): analyst upgrades drive price momentum from clinical trial.

IOVA jumped out to nice gains during yesterday’s session after announcing promising results for a potential treatment for head, neck, and cervical cancers.

The rally only picked up steam today after an upgrade by H.C. Wainright’s globally recognized analysis group (they set a $22 price target on the stock, suggesting it may have more room to run).

Investors are buying into IOVA’s growth potential, driving it over 25% so far during today’s trading.

We can expect to see more big gainers coming from the pharma development sector in the coming weeks. WIth its value driven by news announcements, these gains are particularly exploitable through the agile trading strategies enabled by a news-analytics platform like News Quantified. As market valuations continue to climb and risk appetites rise, we can only expect to see more capital seeking better yields in pharma R&D—inherently a high-risk, high-reward endeavor.

Diverse Plays, Great Profits: All in a single news day.

Keep checking our blog for daily updates on lucrative new-based stock plays, analyst actions, and more!

We analyze news events ranging from clinical trials in the pharmaceutical industry to routine earnings releases to major geopolitical shakeups.

Or, if you’re ready to move beyond the blog and experience the power of hedge-fund caliber news analysis in a package that’s accessible to small investors, click here to sign up for a free training today. You’ll see how easy to use our platform really is—and how many profitable trades it can unlock

A powerful news analytics platform like News Quantified not only makes it easy to track the news, but to quickly compare news events with key financial information. We make it simple to find strong, diverse plays in any market environment.

How are you using the news to earn market-beating profits? How would you use the news if you had access to a real-time platform like News Quantified?  Let us know in the comments below.

Leave a comment